Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

GILD Relative to the S&P 500

GILD Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Gilead Sciences, Inc. (NASD:GILD) seasonal charts above shows that a Buy Date of May 31 and a Sell Date of October 27 has resulted in a geometric average return of 4.76% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 15 of those periods. This is a good rate of success, but the return underperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 2.46% per year.

The seasonal timeframe correlates Fairly Well with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead’s acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead’s exposure to cell therapy and noncell therapy in oncology.

To download GILD seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: GILD